Analgesic effect of intravenous pamidronate on chronic back pain due to osteoporotic vertebral fractures.
Pamidronate, a bisphosphonate analogue has been evaluated in a retrospective study for its analgesic effect on chronic back pain due to vertebral fractures in 26 patients suffering from senile osteoporosis or glucocorticoid-induced osteoporosis. Sixty milligrams of pamidronate was administered intravenously every 3 months for one year. After three months of treatment, the pain score fell from 3.2 +/- 0.1 to 1.2 +/- 0.2 in both groups. In conclusion, intravenous pamidronate seems to be a valuable treatment for chronic back pain due to osteoporotic vertebral fractures.
Gangji
V
V
Rheumatology Department, H pital Erasme, Université Libre de Bruxelles, Brussels, Belgium.
Appelboom
T
T
D000203:Activities of Daily Living; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001416:Back Pain / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology / Q000534:rehabilitation; D004164:Diphosphonates / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D010024:Osteoporosis / Q000150:complications* / Q000503:physiopathology; D010147:Pain Measurement; D000077268:Pamidronate; D012189:Retrospective Studies; D016103:Spinal Fractures / Q000209:etiology* / Q000503:physiopathology; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D004164:Diphosphonates; D000077268:Pamidronate